⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16539 | 0.86 | — | — | |
| SCHEMBL8112356 | 0.69 | — | — | |
| SCHEMBL62472 | 0.69 | — | — | |
| SCHEMBL8841950 | 0.69 | — | — | |
| Lithium SCHEMBL30706491 | 0.67 | — | — | |
| SCHEMBL30706490 | 0.67 | — | — | |
| SCHEMBL181346 | 0.52 | — | — | |
| SCHEMBL118287 | 0.52 | — | — | |
| Ammonia Solution, Strong SCHEMBL30978376 | 0.49 | — | — | |
| SCHEMBL30978372 | 0.49 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118338916-A | Multifunctional compounds for use in medical imaging and therapy | 安特络手术解决方案公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240158403-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| CN-117965536-A | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-11932646-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-03-19 | — | — | US | disclosed |
| CN-108135921-B | Oligonucleotide compositions and methods thereof | 波涛生命科学有限公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-116323565-A | 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-115974851-A | 2-oxo-3-azabicyclo [3.1.0] hexane derivatives | 华领医药技术（上海）有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-109475536-B | Combination of a PD-l antagonist and a RAF inhibitor for the treatment of cancer | 百济神州有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220135573-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254682-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-02-22 | — | — | US | disclosed |
| US-20060122156-A1 | Heteroaryl compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2006053227-A2 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006053109-A1 | HETEROARYL COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20050282809-A1 | Heteroaryl-hydrazone compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-12-22 | — | — | US | disclosed |
| US-20050250774-A1 | Pyridine compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| US-20050250770-A1 | Fused heterocyclic compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| WO-2005074598-A2 | NITROXYL PROGENITOR COMPOUNDS AND METHODS OF USE | JOHNS HOPKINS UNIVERSITY (US) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005046698-A1 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005046604-A2 | HETEROARYL-HYDRAZONE COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005046603-A2 | PYRIDINE COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |